Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial
Multicenter trial demonstrates 84% complete response rate in patients with follicular lymphoma, indicating effective immunomodulation with Mosunetuzumab and Lenalidomide.
Key Points
Eighty-four percent of patients achieved complete response using Mosunetuzumab and low-dose Lenalidomide, showing significant efficacy.
Primary response assessed via PET-CT revealed high rates of minimal residual disease negativity in 93% of responders.
Trial utilized a multicenter approach, administering therapy for up to 12 cycles based on interim assessments.
Results indicate that cytokine release syndrome occurred in 27% of patients, highlighting the safety profile of the treatment.